| 05/08/12 | AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results|
REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2012.
Net loss for the first quarter of 2012 was $7.1 million, or $0.36 per share, compared with a net loss of $3.2 million, or $0.30 per share, for... |
|  | | 04/17/12 | AcelRx Pharmaceuticals Announces Hiring of Kim Gaumer as Vice President, Regulatory Affairs and Quality Assurance| REDWOOD CITY, Calif., April 17, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Kimberley Gaumer to the position of Vice President, Regulatory Affairs and Quality Assurance reporting to Richard King, President and Chief Executive Officer. In this role, Ms. Gaumer will lead all global r... |
| | | 04/12/12 | AcelRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab® PCA System, for the Treatment of Acute Post-Operative Pain| First Subject Dosed in Open-Label, Active-Comparator Trial
REDWOOD CITY, Calif., April 12, 2012 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported dosing of the first patient in the second of three planned Phase 3 studies that will form the basis of a planned New Drug Application (NDA) for the... |
| | | 04/11/12 | AcelRx Pharmaceuticals Receives Two Notices of Allowance for Small-Volume Oral Transmucosal Dosage Forms| First US allowances could provide for intellectual property protection for AcelRx pipeline of NanoTab® pain products until at least 2029.
REDWOOD CITY, Calif., April 11, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Patent and Trademark Office (USPTO) has issued AcelRx two Notices of Allowance fo... |
| | | 03/20/12 | AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results|
REDWOOD CITY, Calif., March 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.
Net loss for the fourth quarter of 2011 was $6.4 million, or $0.33 per share, compared with a net loss of $3.5 million, or $5.23 per share,... |
| | | 03/06/12 | AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain| First Subject Dosed in Abdominal Surgery Trial with Top-Line Data Expected in H2 2012
REDWOOD CITY, Calif., March 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported dosing of the first patient in a Phase 3 study for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patien... |
| | | 02/21/12 | AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences|
REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences, one in New York City, NY and one in Boston, MA, over the coming weeks as follows:
Citi 2012 Global Hea... |
| | | 01/31/12 | AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012|
REDWOOD CITY, Calif., Jan. 31, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported that the two remaining items required by the FDA prior to the initiation of the Phase 3 clinical program for ARX-01, specifically software verification and validation of the ARX-01 system, are progressing... |
| |
|
Print Page | 
E-mail Page | 
RSS Feeds